While the AMPK-activating and therapeutic mechanisms of AMPK remain to be fully understood (or demonstrated clinically in certain contexts), preclinical studies have shown consistent reductions in hepatic steatosis in HFD-fed mice through AMPK-dependent and independent mechanisms (17). Here, PRKAA2 is linked to fatty liver disease.